| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 4,216 | 3,871 | ||
| General and administrative | 2,867 | 3,002 | ||
| Total operating expenses | 7,083 | 6,873 | ||
| Loss from operations | -7,083 | -6,873 | ||
| Interest income | 292 | 272 | ||
| Total non-operating income | 292 | 272 | ||
| Net loss | -6,791 | -6,601 | ||
| Net loss per common share, basic (in dollars per share) | -0.06 | -0.07 | ||
| Net loss per common share, diluted (in dollars per share) | -0.06 | -0.07 | ||
| Weighted-average common shares outstanding, basic (in shares) | 108,396,260 | 98,558,567 | ||
| Weighted-average common shares outstanding, diluted (in shares) | 108,396,260 | 98,558,567 | ||
SELLAS Life Sciences Group, Inc. (SLS)
SELLAS Life Sciences Group, Inc. (SLS)